Phase1 may demonstrate target engagement, page-29

No, I have not. The only thing is that they hired a medical director year ago and then this paper by Cherny. By this Light Chain Amyloidosis, they could get back to orphan status hunting with PBT2. But why to apply a patent, if you do not need it. May be PBT434 is so much better than PBT2 in all respects and later research has confirmed that ???. PBT2 is not so strong a mitochondrion drug than PBT434 is and when treating mitochondrion diseases ( AD, PD etc), that is what you need. Not anything close to it. I think that LCA disease is also a mitochondrion disease, but I am not sure.